IN8bio Stock Jumps After An Update From Leukemia Trial

IN8bio Inc INAB has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia patients undergoing haploidentical hematopoietic stem cell transplant (HSCT). 

  • The three patients with relapsed acute myeloid leukemia (AML) treated to date demonstrate that allogeneic gamma-delta T cell therapy has a manageable toxicity profile with the potential for durable responses in high-risk patients. 
  • All three INB-100 treated patients remain in remission, with two patients in remission at 18 and 20 months, respectively. 
  • No treatment-related grade 3 or greater adverse events, infusion reactions, or dose-limiting toxicities were observed. 
  • The trial continues to track these patients and enroll additional patients, with additional data expected in 2022.
  • Price Action: INAB shares are up 2.16% at $5.67 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralacute myeloid leukemiaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!